IQVIA 报告第一季度业绩强劲，超出分析师预期

IQVIA Holdings Inc. 公布了 2024 年第一季度强劲的财务业绩，收入增长 2.9%，达到 37.37 亿美元（不包括转嫁，研发解决方案部门增长 6.9%）。该公司调整后每股收益为 2.54 美元，超出了分析师的预期，收入也超出了预期，达到 37.4 亿美元。 IQVIA 的财务状况依然稳健，拥有 14 亿美元的现金和等价物，并保持强劲的积压订单和订单出货比，表明未来收入潜力强劲。

IQVIA Holdings Inc. Reports Solid Financial Performance in First Quarter of 2024

IQVIA Holdings Inc. 公布 2024 年第一季度稳健的财务业绩

IQVIA Holdings Inc. (NYSE: IQV), a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, has released its financial results for the first quarter of 2024, demonstrating continued strength and growth across its diverse service segments.

IQVIA Holdings Inc.（纽约证券交易所股票代码：IQV）是一家为生命科学行业提供先进分析、技术解决方案和临床研究服务的领先提供商，该公司公布了 2024 年第一季度的财务业绩，展示了其多元化业务的持续实力和增长。服务领域。

Revenue and Segment Performance

收入和部门表现

IQVIA reported total revenue of $3,737 million for the first quarter, representing a 2.3% increase on a reported basis and a 2.9% increase at constant currency compared to the same period in 2023. Notably, the Research & Development Solutions (R&DS) segment exhibited robust growth, with revenue increasing by 3.4% on a reported basis and 3.8% at constant currency. Excluding the impact of pass-throughs, the R&DS segment saw an impressive 6.9% growth on a reported basis.

IQVIA 报告第一季度总收入为 37.37 亿美元，与 2023 年同期相比，报告基础上增长 2.3%，按固定汇率计算增长 2.9%。值得注意的是，研发解决方案 (R&DS) 部门表现强劲增长，收入按报告计算增长 3.4%，按固定汇率计算增长 3.8%。据报告，排除转嫁的影响，研发部门实现了 6.9% 的惊人增长。

The company's contracted backlog in R&DS reached $30.1 billion, representing a 7.9% year-over-year increase. Approximately $7.7 billion of this backlog is anticipated to convert to revenue within the next twelve months, indicating a strong pipeline for future growth. The first-quarter book-to-bill ratio was a favorable 1.23x, underscoring the company's ability to drive future revenue.

公司研发合同积压金额达301亿美元，同比增长7.9%。其中大约 77 亿美元的积压订单预计将在未来 12 个月内转化为收入，这表明未来增长的渠道强劲。第一季度的订单出货比为 1.23 倍，凸显了该公司推动未来收入的能力。

Financial Position

财务状况

IQVIA Holdings' financial position remained robust during the first quarter. As of March 31, 2024, the company held cash and cash equivalents totaling $1.4 billion. Net debt stood at $12.09 billion, resulting in a net leverage ratio of 3.38x trailing twelve-month Adjusted EBITDA.

IQVIA Holdings 第一季度的财务状况依然强劲。截至2024年3月31日，该公司持有现金及现金等价物总计14亿美元。净债务为 120.9 亿美元，过去 12 个月的调整后 EBITDA 净杠杆率为 3.38 倍。

The company generated an operating cash flow of $522 million and a free cash flow of $377 million for the first quarter. These positive cash flow metrics demonstrate IQVIA's financial health and ability to generate substantial cash flows, further solidifying its position as a leader in the life sciences industry.

该公司第一季度运营现金流为 5.22 亿美元，自由现金流为 3.77 亿美元。这些积极的现金流量指标表明 IQVIA 的财务状况良好，并且有能力产生大量现金流，进一步巩固了其作为生命科学行业领导者的地位。

Earnings and Guidance

收益和指导

IQVIA surpassed analysts' expectations for both EPS and revenue in the first quarter. Adjusted diluted EPS came in at $2.54, slightly above the projected $2.48. Revenue of $3.74 billion comfortably exceeded the anticipated $3.7 billion, signaling stronger-than-expected top-line growth.

IQVIA 第一季度每股收益和营收均超出分析师预期。调整后稀释后每股收益为 2.54 美元，略高于预期的 2.48 美元。收入 37.4 亿美元轻松超过预期的 37 亿美元，表明营收增长强于预期。

Despite the challenging global economic environment, IQVIA has reaffirmed its full-year 2024 guidance, expressing confidence in its business outlook. The company expects full-year revenue to range between $15.325 billion and $15.575 billion on a reported basis, factoring in the impact of currency fluctuations. This guidance implies a growth rate of 2.3 to 3.9%, with an estimated foreign exchange headwind of approximately 100 basis points.

尽管全球经济环境充满挑战，IQVIA 仍重申了 2024 年全年指引，表达了对其业务前景的信心。考虑到货币波动的影响，该公司预计全年营收将在 153.25 亿美元至 155.75 亿美元之间。该指导意味着增长率为 2.3% 至 3.9%，预计外汇阻力约为 100 个基点。

IQVIA anticipates its full-year Adjusted EBITDA to be between $3,700 million and $3,800 million, representing a growth of 3.7 to 6.5%. The Adjusted Diluted EPS guidance is set at $10.95 to $11.25, indicating a year-over-year increase of 7.4 to 10.3%.

IQVIA 预计全年调整后 EBITDA 将在 37 亿美元至 38 亿美元之间，增长 3.7% 至 6.5%。调整后稀释每股收益指导值为 10.95 美元至 11.25 美元，同比增长 7.4% 至 10.3%。

Conclusion

结论

IQVIA Holdings Inc.'s first-quarter financial performance highlights the company's operational resilience and the effectiveness of its business strategy. The solid growth in its R&DS segment, strong financial position, and positive cash flow generation underscore IQVIA's position as a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company's reaffirmed guidance for the full year 2024 reflects its confidence in its ability to continue delivering value to its clients and stakeholders in the face of global uncertainties.

IQVIA Holdings Inc. 第一季度的财务业绩凸显了该公司的运营弹性和业务战略的有效性。研发部门的稳健增长、强劲的财务状况和正现金流的产生凸显了 IQVIA 作为生命科学行业先进分析、技术解决方案和临床研究服务领先提供商的地位。该公司重申的 2024 年全年指引反映了其在面对全球不确定性的情况下继续为客户和利益相关者提供价值的能力的信心。